surpass-cvot tirzepatide Comparison of and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide
Pay in 4 interest-free payments of $7.15 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5






























